Learning Objectives
- Summarize the evolving first‑line treatment landscape in endometrial cancer, including the clinical rationale for immunotherapy‑chemotherapy combinations across biomarker subgroups.
- Evaluate mature long‑term efficacy and safety data presented at SGO 2026, with emphasis on durability of benefit, survival outcomes, and patient‑centred considerations.
- Integrate current long‑term evidence into clinical practice, informing treatment selection, sequencing, and patient discussions, while remaining mindful of emerging therapies and future research directions.
Moderators
Speakers
This program has been made possible through unrestricted support from GSK.